CGEM logo

CGEM
Cullinan Oncology Inc

488
Mkt Cap
$859.18M
Volume
471,167.00
52W High
$16.74
52W Low
$5.68
PE Ratio
-3.73
CGEM Fundamentals
Price
$13.84
Prev Close
$13.98
Open
$14.00
50D MA
$14.20
Beta
1.18
Avg. Volume
682,675.00
EPS (Annual)
-$3.72
P/B
2.34
Rev/Employee
$0.00
$235.95
Loading...
Loading...
News
all
press releases
The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...
News Placeholder
More News
News Placeholder
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 8,000 shares of the business's stock in a transaction that occurred on Tuesday, May 5th. The shares were...
News Placeholder
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5.6% - Time to Sell?
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5.6% - Here's What Happened...
News Placeholder
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a h...
News Placeholder
Cullinan Therapeutics (NASDAQ:CGEM) Trading 8.5% Higher - Here's Why
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 8.5% - Time to Buy...
News Placeholder
Cullinan Therapeutics (NASDAQ:CGEM) Receives "Buy" Rating from BTIG Research
BTIG Research reiterated a "buy" rating and issued a $38.00 price objective on shares of Cullinan Therapeutics in a report on Monday...
News Placeholder
Research Analysts Issue Forecasts for CGEM Q1 Earnings
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for Cullinan Therapeutics in a research report issued to...
News Placeholder
Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Thursday
Cullinan Therapeutics (NASDAQ:CGEM) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
News Placeholder
HC Wainwright Forecasts Strong Price Appreciation for Cullinan Therapeutics (NASDAQ:CGEM) Stock
HC Wainwright increased their price target on shares of Cullinan Therapeutics from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday...
News Placeholder
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for zipalertinib for the treatment of patients with locally advanced or metastatic...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available